Skip to main content

Advertisement

SpringerLink
Log in

Ghrelin Could be a Candidate for the Prevention of In-Stent Restenosis

  • REVIEW ARTICLE
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Percutaneous coronary intervention is a revolutionary treatment for ischemic heart disease, but in-stent restenosis (ISR) remains a clinical challenge. Inflammation, smooth muscle proliferation, endothelial function impairment, and local thrombosis have been identified as the main mechanisms for ISR. Considering the multifactorial mechanisms of ISR, a novel therapeutic agent with multiple bioactivities is required. Ghrelin is a novel gut–brain peptide predominantly produced by the stomach, and has been shown to play a role in various cardiovascular activities, such as increasing myocardial contractility, improving cardiac output, and inhibiting ventricular remodeling, as well as attenuating cardiac ischemia-reperfusion injury. Recent studies have demonstrated that ghrelin effectively inhibits vascular inflammation and vascular smooth muscle cell proliferation, repairs endothelial cells, promotes vascular endothelial function, inhibits platelet aggregation, and exerts antithrombotic effects. These findings suggest that ghrelin may be an innovative therapeutic candidate for the prevention and treatment of ISR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kim MS, Dean LS. In-stent restenosis. Cardiovasc Ther. 2011;29:190–8.

    Article  PubMed  Google Scholar 

  2. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–60.

    Article  PubMed  CAS  Google Scholar 

  3. Garcia EA, Korbonits M. Ghrelin and cardiovascular health. Curr Opin Pharmacol. 2006;6:142–7.

    Article  PubMed  CAS  Google Scholar 

  4. Granata R, Baragli A, Settanni F, Scarlatti F, Ghigo E. Unraveling the role of the ghrelin gene peptides in the endocrine pancreas. J Mol Endocrinol. 2010;45:107–18.

    Article  PubMed  CAS  Google Scholar 

  5. Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell. 2008;132:387–96.

    Article  PubMed  CAS  Google Scholar 

  6. Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation. 2004;110:3674–9.

    Article  PubMed  CAS  Google Scholar 

  7. Soeki T, Kishimoto I, Schwenke DO, Tokudome T, Horio T, Yoshida M, et al. Ghrelin supresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. Am J Physiol Heart Circ Physiol. 2008;294:H426–32.

    Article  PubMed  CAS  Google Scholar 

  8. Chang L, Ren Y, Liu X, Li WG, Yang J, Geng B, et al. Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart. J Cardiovasc Pharmacol. 2004;43:165–70.

    Article  PubMed  CAS  Google Scholar 

  9. Drachman DE, Simon DI. Inflammation as a mechanism and therapeutic target for in-stent restenosis. Curr Atheroscler Rep. 2005;7:44–9.

    Article  PubMed  CAS  Google Scholar 

  10. Waseem T, Duxbury M, Ito H, Ashley SW, Robinson MK. Exogenous Ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways. Surgery. 2008;143:334–42.

    Article  PubMed  Google Scholar 

  11. Sharma V, McNeill JH. The emerging roles of leptin and Ghrelin in cardiovascular physiolosy and pathophysioloy. Curr Vasc Pharmacol. 2005;3:169–80.

    Article  PubMed  CAS  Google Scholar 

  12. Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL, et al. Ghrelin inhibits pro-inflammatory responses and nuclear factor kappaB activation in human endothelial cells. Circulation. 2004;109:2221–6.

    Article  PubMed  CAS  Google Scholar 

  13. Deng B, Xie XM, Chen XB. Relationship of ghrelin level to inflammatory factor and endothelial relaxation function in metabolic syndrome patients. Chin J Arterioscler. 2010;18:487–91.

    CAS  Google Scholar 

  14. Granado M, Priego T, Martin AI, Villanúa MA, López-Calderón A. Anti-inflammatory effect of the Ghrelin agonist growth hormone releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab. 2005;288:E486–92.

    Article  PubMed  CAS  Google Scholar 

  15. Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, et al. Ghrelin inhibits leptin-and activation-induced pro-inflammatory cytokine expression by human monocytes and T cells. J Clin Investig. 2004;114:57–66.

    PubMed  CAS  Google Scholar 

  16. Zhao D, Zhan Y, Zeng H, Moyer MP, Mantzoros CS, Pothoulakis C. Ghrelin stimulates interleukin-8 gene expression through protein kinase C-mediated NF-κB pathway in human colonic epitheial cells. J Cell Biochem. 2006;97:1317–27.

    Article  PubMed  CAS  Google Scholar 

  17. Xia Q, Pang W, Pan H, Zheng Y, Kang JS, Zhu SG. Effects of Ghrelin on the proliferation and secretion of splenic T lymphocytes in mice. Regul Pept. 2004;122:173–8.

    Article  PubMed  CAS  Google Scholar 

  18. Chow KB, Cheng CH, Wise H. Anti-inflammatory activity of ghrelin in human carotid artery cells. Inflammation. 2009;32:402–9.

    Article  PubMed  CAS  Google Scholar 

  19. Skilton MR, Nakhla S, Sieveking DP, Caterson ID, Celermajer DS. Pathophysiological levels of the obesity related peptides resistin and ghrelin increase adhesion molecule expression on human vascular endothelial cells. Clin Exp Pharmacol Physiol. 2005;32:839–44.

    Article  PubMed  CAS  Google Scholar 

  20. Huang CX, Yuan MJ, Huang H, Wu G, Liu Y, Yu SB, et al. Ghrelin inhibits post-infarct myocardial remodeling and improves cardiac function through anti-inflammation effect. Peptides. 2009;30:2286–91.

    Article  PubMed  CAS  Google Scholar 

  21. Marks AR. Rapamycin: signaling in vscular smooth muscle. Transplant Proc. 2003;35:231S–3S.

    Article  PubMed  CAS  Google Scholar 

  22. Willis AI, Pierre-Paul D, Stunpio BE, Gahtan V. Vascular smooth muscle cell migration:current research and clinical implications. Vasc Endovasc Surg. 2004;38:11–23.

    Article  CAS  Google Scholar 

  23. Chen J, Han Y, Lin C, Zhen Y, Song X, Teng S, et al. PDGF-D contributes to neointimal hyperplasia in rat model of vessel injury. Biochem Biophys Res Commun. 2005;29:976–83.

    Article  Google Scholar 

  24. Lavezzi AM, Ottaviani G, Matturri L. Biology of the smooth muscle cells in human atherosclerosis. APMIS. 2005;113:112–21.

    Article  PubMed  Google Scholar 

  25. Deng DX, Spin JM, Tsalenko A, Vailaya A, Ben-Dor A, Yakhini Z, et al. Molecular signatures determining coronary artery and saphenous vein smooth muscle cell phenotypes: distinct responses to stimuli. Arterioscler Thromb Vasc Biol. 2006;26:1058–65.

    Article  PubMed  CAS  Google Scholar 

  26. Zhan M, Yuan F, Liu H, Chen H, Qiu X, Fang W. Inhibition of proliferation and apoptosis of vascular smooth muscle cells by ghrelin. Acta Biochim Biophys Sin (Shanghai). 2008;40:769–76.

    Google Scholar 

  27. Rossi F, Castelli A, Bianco MJ, Bertone C, Brama M, Santiemma V. Ghrelin inhibits contraction and proliferation of human aortic smooth muscle cells by cAMP/PKA pathway activation. Atherosclerosis. 2009;203:97–104.

    Article  PubMed  CAS  Google Scholar 

  28. Li GZ, Jiang W, Zhao J, Pan CS, Cao J, Tang CS, et al. Ghrelin blunted vascular calcification in vivo and in vitro in rats. Regul Pept. 2005;129:167–76.

    Article  PubMed  CAS  Google Scholar 

  29. Liang QH, Jiang Y, Zhu X, Cui RR, Liu GY, Liu Y, et al. Ghrelin attenuates the osteoblastic differentiation of vascular smooth muscle cells through the ERK pathway. PLoS One. 2012;7:e33126.

    Article  PubMed  CAS  Google Scholar 

  30. Hu CZ, Cao YL, Huo HY, Zhao WH, Hu J. Inhibitory effect of ghrelin on nicotine-induced VCAM-1expression in human umbilical vein endothelial cells. J Cardiovasc Pharmacol. 2009;53:241–5.

    Article  PubMed  CAS  Google Scholar 

  31. Xu YP, Zhu JJ, Cheng F, Jiang KW, Gu WZ, Shen Z, et al. Ghrelin ameliorates hypoxia-induced pulmonary hypertension via phospho-GSK3β/β-catenin signaling in neonatal rats. J Mol Endocrinol. 2011;47:33–43.

    Article  PubMed  CAS  Google Scholar 

  32. Shimizu Y, Nagaya N, Teranishi Y, Imazu M, Yamamoto H, Shokawa T, et al. Ghrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats. Biochem Biophys Res Commun. 2003;310:830–5.

    Article  PubMed  CAS  Google Scholar 

  33. Tesauro M, Schinzari F, Iantorno M, Rizza S, Melina D, Lauro D, et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation. 2005;112:2986–92.

    PubMed  CAS  Google Scholar 

  34. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI3-kinase/AKT. J Cell Biol. 2002;159:1029–37.

    Article  PubMed  CAS  Google Scholar 

  35. Zhan H, Liu G, Wang Q, Ding L, Cai H, Jiang H, et al. Effect of Ghrelin on human endothelial cells apoptosis induced by high glucose. Biochem Biophys Res Commun. 2007;362:677–81.

    Article  Google Scholar 

  36. Deng B, Fang L, Chen X, Chen M, Xie X. Effect of ghrelin on angiotensin II induced human umbilicus vein endothelial cell oxidative stress and endothelial cell injury. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010;35:1037–47.

    PubMed  CAS  Google Scholar 

  37. Xiang Y, Li Q, Li M, Wang W, Cui C, Zhang J. Ghrelin inhibits AGEs-induced apoptosis in human endothelial cells involving ERK1/2 and PI3K/Akt pathways. Cell Biochem Funct. 2011;29:149–55.

    Article  PubMed  CAS  Google Scholar 

  38. Rossi F, Castelli A, Bianco MJ, Bertone C, Brama M, Santiemma V. Ghrelin induces proliferation in human aortic endothelial cells via ERK1/2 and PI3K/Akt activation. Peptides. 2008;29:2046–51.

    Article  PubMed  CAS  Google Scholar 

  39. Hedayati N, Annambhotla S, Jiang J, Wang X, Chai H, Lin PH, et al. Growth hormone-releasing peptite ghrelin inhibits homocysteine-induced endothelial dysfunction in porcine coronary arteries and human endothelial cells. J Vasc Surg. 2009;49:199–207.

    Article  PubMed  Google Scholar 

  40. Rossi F, Bertone C, Petricca S, Santiemma V. Ghrelin inhibits angiotensin-II induced migration of human aortic endothelial cells. Atherosclerosis. 2007;192:291–7.

    Article  PubMed  CAS  Google Scholar 

  41. Conconi MT, Nico B, Guidolin D, Baiguera S, Spinazzi R, Rebuffat P, et al. Ghrelin inhibits FGF-2-mediated angiogenesis in vitro and in vivo. Peptides. 2004;25:2179–85.

    Article  PubMed  CAS  Google Scholar 

  42. Ahluwalia A, Li A, Cheng G, Deng X, Tarnawski AS. Reduced ghrelin in endothelial cells plays important mechanistic role in aging-related impairment of angiogenesis. J Physiol Pharmacol. 2009;60:29–34.

    PubMed  CAS  Google Scholar 

  43. Ferns GA, Avades TY. The mechanisms of coronary restenosis:insight from experimental models. Int J Exp Pathol. 2000;81:63–88.

    Article  PubMed  CAS  Google Scholar 

  44. Elbatarny HS, Netherton SJ, Ovens JD, Ferguson AV, Maurice DH. Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases. Eur J Pharmacol. 2007;558:7–13.

    Article  PubMed  CAS  Google Scholar 

  45. Kantorova E, Chomova M, Kurca E, Sivak S, Zelenak K, Kučera P, et al. Leptin, adiponectin and ghrelin, new potential mediators of ischemic stroke. Neuroendocrinol Lett. 2011;32:716–21.

    PubMed  CAS  Google Scholar 

  46. Arici OF, Cetin N. Protective role of ghrelin against carbon tetrachloride (CCl4)-induced coagulation disturbances in rats. Regul Pept. 2011;166:139–42.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work is in part supported by the Specialized Research Fund for the Doctoral Program of Higher Education (no. 20114404110006).

Author information

Authors and Affiliations

  1. Department of Cardiology, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, 515041, China

    Z. W. Shu, M. Yu, X. J. Chen & X. R. Tan

  2. Molecular Biology Laboratory, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, 515041, China

    Z. W. Shu & M. Yu

Authors
  1. Z. W. Shu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X. J. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. X. R. Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to X. R. Tan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shu, Z.W., Yu, M., Chen, X.J. et al. Ghrelin Could be a Candidate for the Prevention of In-Stent Restenosis. Cardiovasc Drugs Ther 27, 309–314 (2013). https://doi.org/10.1007/s10557-013-6453-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-013-6453-1

Keywords

Search

Navigation